Liquidia Corporation (LQDA) vs Supernus Pharmaceuticals, Inc. (SUPN)
- Liquidia Corporation LQDA 34.35 −1.24%
- Supernus Pharmaceuticals, Inc. SUPN 37.88 −4.27%
Liquidia Corporation and Supernus Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Liquidia Corporation is the larger, with a market value of $3.1B against $2.3B — 1.4× the size. Supernus Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Liquidia Corporation trades at 21.9×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against 24.9%. Liquidia Corporation has the higher net margin (30.7% vs −13.2%) and the higher return on invested capital (121.1% vs −12.4%). Across the 19 metrics below, Liquidia Corporation leads on 14 and Supernus Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | LQDA | SUPN | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 92.54% | 88.07% | 53.94% |
| Operating margin | 37.39% | (15.71%) | 0.00% |
| Net margin | 30.74% | (13.23%) | 0.00% |
| Free cash flow margin | 33.42% | 2.21% | 0.00% |
| Return on equity | 131.82% | (10.49%) | (0.40%) |
| Return on assets | 35.57% | (7.82%) | (3.32%) |
| Return on invested capital | 121.05% | (12.37%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack